Keeping our eyes focused on what we reach for, whether it be an item at the grocery store or a ground ball on the baseball field, may appear… read more.
Genentech, announced that new two-year data from its Phase III studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be… read more.
Health issues for people over sixty commonly involve the heart and other vital organs. So do eye-related conditions such as cataracts and glaucoma, but dry eyes don’t often… read more.
Eating disorders are associated with an increased risk of people with diabetes developing diabetic retinopathy — a condition that can cause blindness if untreated — according to new… read more.
Inhibiting ceramide accumulation in retina protects photoreceptors, improves vision. Researchers from the University of California, Irvine have discovered that the absence of Adiponectin receptor 1 protein (AdipoR1), one… read more.
Horizon Therapeutics plc announced findings of a real-world adherence analysis of Tepezza for the treatment of TED ( Thyroid Eye Disease) at the American Academy of Ophthalmology Annual… read more.
Clinical trial planning underway to test the widely used diabetes drug metformin as a preventive treatment for the blinding eye disease. Scientists have discovered that gene therapy and… read more.
Oregon Health & Science University is part of a national research project investigating stem cell therapy as a potential treatment for glaucoma, the world’s second leading cause of blindness…. read more.
Allergan announced the FDA approval of Vuity (pilocarpine HCl ophthalmic solution) 1.25% for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. Vuity is… read more.
Risk of dementia increases with age-related macular degeneration, cataract and diabetes-related eye disease, but not glaucoma. Age-related macular degeneration, cataract and diabetes-related eye disease are linked to an… read more.
Horizon Therapeutics plc has announced that the first patient has been enrolled in a Phase IV clinical trial evaluating the efficacy and safety of Tepezza for the treatment… read more.
In the paper published in EClinical Medicine by The Lancet, the research team examined lesions of the retina, the inner-most, light-sensitive layer of the eye, to determine if a cardiovascular… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
